WO2024224346 - PROCESS
National phase entry is expected:
Publication Number
WO/2024/224346
Publication Date
31.10.2024
International Application No.
PCT/IB2024/054069
International Filing Date
26.04.2024
Title **
[English]
PROCESS
[French]
PROCÉDÉ
Applicants **
FORMO BIO GMBH
Inventors
BONGARTZ, Kira von
EISENMÜLLER, Melanie
HÖLER, Sebastian
OSORIO, Claudia
ANNIBAL, Andrea
HAMANN, Florian
HOPPENREIJS, Loes
KEPPLER, Julia
BOOM, Remko
Priority Data
2023901257
28.04.2023
AU
2023903032
20.09.2023
AU
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2429 | |
| EPO | Filing, Examination, Granting | 11442 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2418 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,336
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A cost effective and scalable process for the purification of impure sources of beta-lactoglobulin (BLG) is provided, with applicability to impure BLG derived from mammalian sources or derived recombinantly.[French]
L'invention concerne un procédé rentable et évolutif pour la purification de sources impures de bêta-lactoglobuline (BLG), avec une applicabilité à une BLG impure dérivée de sources mammifères ou obtenue par recombinaison.